Evidence map›Paper›PMID 39329327›Full record

ArticleAnnals of medicine2024

Development of a novel nomogram for predicting prognosis of North Chinese with autoimmune cerebellar ataxia.

Chunxia Zhao, Cao Jiang, Decai Tian, Yajun Yao, Tian Song, Huabing Wang, Wangshu Xu

Abstract read
In one paragraph

Article in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chunxia ZhaoDepartment of Neurology, Tianjin Fifth Central Hospital, Tianjin, China.
Cao JiangDepartment of Neurology, Qinhuangdao Funing District People's Hospital, Qinhuangdao, China.
Decai TianDepartment of Neurology, Beijing Tiantan Hospital, Beijing, China.
Yajun YaoDepartment of Neurology, Beijing Tiantan Hospital, Beijing, China.
Tian SongDepartment of Neurology, Beijing Tiantan Hospital, Beijing, China.
Huabing WangDepartment of Neurology, Beijing Tiantan Hospital, Beijing, China.
Wangshu XuDepartment of Neurology, Beijing Tiantan Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to develop a prognostic nomogram which could predict the prognosis of north Chinese patients with autoimmune cerebellar ataxia (ACA) after immunotherapy.

methodsPatients with an initial diagnosis of ACA who accepted first-line immunotherapy at our hospital from March 2018 to May 2023 were retrospectively reviewed. Modified Rankin Scale (mRS) was used to evaluate neurological outcomes. According to the mRS scores after immunotherapy, patients with ACA were divided into good prognosis group (mRS 0-2) and poor prognosis group (mRS 3-6). The nomogram for poor prognosis of ACA patients were built based on logistic regression analysis. The validation of the prognostic model was evaluated by concordance index (C-index), calibration curves, and decision curve analyses (DCAs).

resultsA total of 86 patients with ACA who received immunotherapy at our hospital were included in this study. They were randomly divided into a training cohort (

conclusionWe successfully developed a nomogram to predict poor prognosis for ACA patients using risk factors of age, elevated CSF-ALB and abnormal MRI.

Indexed as

Cerebellar AtaxiaMagnetic Resonance ImagingNomogramsAdultAgedAutoimmune DiseasesChinaEast Asian PeopleFemaleHumansImmunotherapyMaleMiddle AgedPrognosisRetrospective StudiesAutoimmune cerebellar ataxiamodified Rankin Scalenomogrampredictionprognosis

Identifiers

PMID39329327
PMCPMC11441064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.